AUS
NZ
UK
CA
USA
IND
Highlights
- Breakthrough Therapy Designation: GSK5764227 (GSK'227), a B7-H3-targeted ADC, receives FDA recognition for its potential to treat relapsed or refractory osteosarcoma, offering hope to patients with limited options.
- Strong Clinical Backing: Designation supported by promising results from the ARTEMIS-002 phase II trial, which evaluated GSK'227 in osteosarcoma and other sarcomas.
- Global Development: GSK progresses GSK'227 with a global phase I trial and regulatory designations, including PRIME status from the EMA and prior FDA designations for small-cell lung cancer.
GSK plc (LSE:GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational drug GSK5764227 (GSK'227). This B7-H3-targeted antibody-drug conjugate (ADC) is being developed to treat adult patients with relapsed or refractory osteosarcoma, a rare and aggressive bone cancer, who have failed at least two prior lines of therapy.
Expediting Innovation for Osteosarcoma
The Breakthrough Therapy Designation is designed to accelerate the development and review of drugs that show potential for significant improvement over existing treatments for serious conditions. This recognition for GSK'227 is the third regulatory designation for the drug, following the European Medicines Agency's PRIME status and the FDA's earlier Breakthrough Therapy Designation for its application in small-cell lung cancer.
Clinical Evidence from ARTEMIS-002
The FDA designation is based on data from the ARTEMIS-002 phase II clinical trial, conducted by Hansoh Pharma. The study involved more than 60 patients, including 42 with osteosarcoma, and evaluated the efficacy and safety of GSK'227 in patients with relapsed or refractory bone and soft tissue sarcomas. Results from the trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showing encouraging outcomes.
GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma last year and is now advancing the drug globally with a phase I trial to support regulatory approval pathways.
Urgent Need in Osteosarcoma
Osteosarcoma is the most common primary bone cancer, primarily affecting children and young adults, with an annual incidence of 3.3 per million in the US. It accounts for 20–40% of all bone cancers but represents less than 1% of all cancer diagnoses. The prognosis for relapsed or refractory cases is particularly poor, with limited treatment options and no approved therapies for patients who progress after two prior lines of treatment.
